全文获取类型
收费全文 | 9759篇 |
免费 | 592篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 65篇 |
儿科学 | 225篇 |
妇产科学 | 117篇 |
基础医学 | 1145篇 |
口腔科学 | 151篇 |
临床医学 | 965篇 |
内科学 | 2222篇 |
皮肤病学 | 202篇 |
神经病学 | 596篇 |
特种医学 | 263篇 |
外国民族医学 | 2篇 |
外科学 | 1847篇 |
综合类 | 254篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 607篇 |
眼科学 | 184篇 |
药学 | 899篇 |
中国医学 | 167篇 |
肿瘤学 | 512篇 |
出版年
2024年 | 14篇 |
2023年 | 156篇 |
2022年 | 185篇 |
2021年 | 750篇 |
2020年 | 443篇 |
2019年 | 551篇 |
2018年 | 542篇 |
2017年 | 354篇 |
2016年 | 363篇 |
2015年 | 394篇 |
2014年 | 496篇 |
2013年 | 577篇 |
2012年 | 913篇 |
2011年 | 817篇 |
2010年 | 398篇 |
2009年 | 350篇 |
2008年 | 541篇 |
2007年 | 500篇 |
2006年 | 442篇 |
2005年 | 409篇 |
2004年 | 331篇 |
2003年 | 300篇 |
2002年 | 165篇 |
2001年 | 80篇 |
2000年 | 57篇 |
1999年 | 38篇 |
1998年 | 30篇 |
1997年 | 10篇 |
1996年 | 22篇 |
1995年 | 9篇 |
1994年 | 13篇 |
1993年 | 12篇 |
1992年 | 11篇 |
1991年 | 16篇 |
1990年 | 11篇 |
1989年 | 11篇 |
1988年 | 14篇 |
1987年 | 9篇 |
1986年 | 5篇 |
1985年 | 8篇 |
1984年 | 10篇 |
1983年 | 6篇 |
1982年 | 6篇 |
1981年 | 12篇 |
1978年 | 8篇 |
1976年 | 5篇 |
1975年 | 4篇 |
1972年 | 7篇 |
1969年 | 4篇 |
1965年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 515 毫秒
1.
Syed M. Gilani Muhammad Khan Andrea Barbieri Manju L. Prasad 《Diagnostic Histopathology》2021,27(6):263-271
Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid malignancy with high mortality rate. This malignancy arises in thyroid follicular cells either denovo or with an associated differentiated thyroid carcinoma component. Clinically, it usually presents as a rapidly enlarging mass, pain and locally compressive symptoms. Histopathologic variability and heterogeneity often pose diagnostic challenges, especially in scant and paucicellular specimens. This article describes the clinical, histopathologic and molecular features of ATC and also addresses the associated diagnostic limitations and challenges. 相似文献
2.
3.
Ehsan Zarei Elmira Madarshahian Adeleh Nikkhah Soheila Khodakarim 《Journal of tissue viability》2019,28(2):70-74
Background and objective
Pressure ulcer (PU) is one of the important and frequent complications of hospitalization, associated with high treatment costs. The present study was conducted to determine the incidence of PU and its direct treatment costs for patients in intensive care unit (ICU) in Iran.Material and methods
In this retrospective study, medical records of 643 discharged patients from ICU of two selected hospitals were examined. The demographic and clinical data of all patients and data of resources and services usage for patients with PU were extracted through their records. Data analysis was done using logistic regression tests in SPSS 22 software. The cost of PU treatment was calculated for each grade of ulcer.Results
The findings showed that 8.9% of patients developed PU during their stay in ICU. Muscular paralysis (OR?=?5.1), length of stay in ICU (OR?=?4.0), diabetes (OR?=?3.5) age (OR?=?2.9), smoking (OR?=?2.1) and trauma (OR?=?1.4) were the most important risk factors of PU. The average cost of PU treatment varied from USD 12 for grade I PU to USD 66?834 for grade IV PUs. The total treatment costs for all studied patients with PU was estimated at USD 519?991.Conclusion
The cost of PU treatment is significant. Since the preventive measures are more cost-effective than therapeutic measures, therefore, effective preventive interventions are recommended. 相似文献4.
5.
6.
7.
Shafqat R. Chaudhry Ilana S. Lendvai Sajjad Muhammad Philipp Westhofen Johannes Kruppenbacher Lukas Scheef Henning Boecker Dirk Scheele Rene Hurlemann Thomas M. Kinfe 《Brain stimulation》2019,12(3):643-651
Objective
To assay peripheral inter-ictal cytokine serum levels and possible relations with non-invasive vagus nerve stimulation (nVNS) responsiveness in migraineurs.Methods
This double-blinded, sham-controlled study enrolled 48 subjects and measured headache severity, frequency [headache days/month, number of total and mild/moderate/severe classified attacks/month], functional state [sleep, mood, body weight, migraine-associated disability] and serum levels of inflammatory markers [inter-ictal] using enzyme-linked immunoassays at baseline and after 2 months of adjunctive nVNS compared to sham stimulation and suitably matched controls.Results
No significant differences were observed at baseline and after 2 months for headache severity, total attacks/month, headache days/month and functional outcome [sleep, mood, disability] between verum and sham nVNS. However, the number of severe attacks/month significantly decreased in the verum nVNS group and circulating pro-inflammatory IL-1β was elevated significantly in the sham group compared to nVNS. Levels of anti-inflammatory IL-10 were significantly higher at baseline in both groups compared to healthy controls, but not at 2 months follow-up [p?<?0.05]. Concentrations of high-mobility group box-1 (HMGB-1), IL-6, tumor-necrosis factor-α (TNF-α), leptin, adiponectin, ghrelin remained unchanged [p?>?0.05]. No severe device-/stimulation-related adverse events occurred.Conclusion
2 months of adjunctive cervical nVNS significantly declined the number of severe attacks/month. Pro-inflammatory IL-1β plasma levels [inter-ictal] were higher in sham-treated migraine patients compared to verum nVNS. However, pro- [IL-6, HMGB-1, TNF-α, leptin] and anti-inflammatory [IL-10, adiponectin, ghrelin] mediators did not differ statistically. Profiling of neuroinflammatory circuits in migraine to predict nVNS responsiveness remains an experimental approach, which may be biased by pre-analytic variables warranting large-scale biobank-based systematic investigations [omics]. 相似文献8.
Raffaella Marcheselli Alessia Bari Tamar Tadmor Luigi Marcheselli Maria Christina Cox Robel Papotti Angela Ferrari Luca Baldini Paolo Gobbi Ilana Levy Giuseppe Pugliese Massimo Federico Aaron Polliack Samantha Pozzi Stefano Sacchi 《Hematological oncology》2020,38(4):439-445
The main purpose of this study was to assess whether it is possible to improve the prognostic impact of international prognostic index (IPI) score by combining it with peripheral blood counts. Thus, we evaluated the prognostic power of lymphocyte, neutrophil, and monocyte counts in 520 patients with diffuse large B cell lymphoma treated with R-CHOP, confirming that these parameters have a strong impact on overall survival (OS). Using revised IPI (R-IPI), 44% of patients were categorized as poor-risk and showed an OS at 5 years of 46%. As OS at 5 years of the 520 patients is 67%, it is clearly evident that R-IPI tends to overestimate the proportion of patients with poor prognosis. Accordingly, in an attempt to improve the discriminating power of R-IPI, we evaluated and compared three different scores by combining the neutrophil lymphocyte ratio (NLR) and absolute monocyte count (AMC) with the following values: (a) IPI score 3-5, (b) age > 60 years and performance status, (c) age ≥ 65 years and LDH > ULN. The three indexes studied, had a similar 5 years OS for the high-risk group (46%-52%), but the proportion of patients classified as poor-risk were 37%, 20%, and 32%, respectively, which are lower than 44% identified with R-IPI. Thus, while R-IPI overestimates the number of high-risk patients, after applying our models, it is possible to recognize patients who are truly at high-risk. Of the three scores, the most accurate appears to be that based on NLR, AMC, LDH > ULN and age ≥ 65 years, which identifies 32% of high-risk patients, correlating well with what is seen in clinical practice. 相似文献
9.
10.
Evaluation of NMU-Induced Breast Cancer Treated with Sirolimus and Sunitinib on Breast Cancer Growth 下载免费PDF全文
Nurul Fathiyatul Nabila JaffarMuhammad Shahidan Muhammad SakriHasnan JaafarWan Faiziah Wan Abdul RahmanTengku Ahmad Damitri Al-Astani Tengku Din 《Asian Pacific journal of cancer prevention》2020,21(10):2919-2925
Objective: To analyze the effect of sirolimus and sunitinib in blocking the tumor growth and to evaluate the expressions of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor-2 (HER2/neu) after treated with sirolimus and sunitinib. Methods: Thirty-two female Sprague Dawley rats at age 21-days old were administered intraperitoneally with N-Methyl-N-Nitroso Urea (NMU), dosed at 70mg/kg body weight. The rats were divided into 4 groups; Group 1 (Control, n=8), Group 2 (Sirolimus, n=8), Group 3 (Sunitinib, n=8) and Group 4 (Sirolimus+Sunitinib, n=8), being treated twice when the tumor reached the size of 14.5±0.5 mm and subsequently sacrificed after 5 days. The protein expressions of ER, PgR and HER2/neu of the tumor tissues were evaluated by using immunohistochemistry analysis. Results: Treatment with sirolimus alone lowered expressions of ER and PgR of breast cancer and reduced tumor size. There was no significant difference of ER and PgR expressions between control and sunitinib treated tumor. Sunitinib treated tumors reduce in diameter after the first treatment, however the diameter increases after the second treatment. Histologically, sunitinib treated tumor did not show any aggressive invasive carcinoma of no special type (NST) histological subtypes. In addition, all NMU-induced tumors are HER2/neu-negative scoring. Conclusion: Sirolimus is neither synergistic nor additive with sunitinib for breast cancer treatment. 相似文献